This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Agomelatine

Novartis AG

Drug Names(s): AGO178, AG0178, S-20098, Thymanax (EU), Valdoxan (EU)

Description: AGO178 (agomelatine) acts as an agonist at melatonin (MT1 and MT2) receptors with additional 5-HT2C (serotonin) antagonist properties.

Deal Structure: In March 2006, Novartis and Servier signed a license agreement for agomelatine. Under the terms of the agreement, Novartis has acquired the exclusive rights to further develop and market agomelatine in the US and several other countries. Servier retained the rights to develop and market the product in the rest of the world. The financial terms of this agreement were not disclosed.

Partners: Les Laboratoires Servier


Agomelatine News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug